Akero Therapeutics
Akero Therapeutics is a clinical-stage company dedicated to developing transformational treatments for serious metabolic diseases, with a focus on metabolic dysfunction-associated steatohepatitis (MASH). They leverage novel biology, including the natural hormone FGF21, to address high unmet medical needs through innovative therapies. Their mission is to restore whole-body metabolic balance and reverse fibrosis, aiming to improve patients' lives worldwide.
Industries
Nr. of Employees
small (1-50)
Akero Therapeutics
Products
Efruxifermin
An investigational Fc-FGF21 fusion protein being evaluated for the treatment of MASH across moderate to advanced fibrosis and compensated cirrhosis.
Efruxifermin (EFX) Compensated cirrhosis
Efruxifermin evaluated in Phase 3 clinical trials for compensated cirrhosis (F4) due to MASH.
pegozafermin
An FGF21 analog investigated for reducing triglycerides and treating metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia.
efimosfermin
An FGF21 analog evaluated for normalizing liver fat and improving metabolic health in patients with metabolic liver disease.
Efruxifermin
An investigational Fc-FGF21 fusion protein being evaluated for the treatment of MASH across moderate to advanced fibrosis and compensated cirrhosis.
Efruxifermin (EFX) Compensated cirrhosis
Efruxifermin evaluated in Phase 3 clinical trials for compensated cirrhosis (F4) due to MASH.
pegozafermin
An FGF21 analog investigated for reducing triglycerides and treating metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia.
efimosfermin
An FGF21 analog evaluated for normalizing liver fat and improving metabolic health in patients with metabolic liver disease.
News & Updates
Reported topline results demonstrating statistically significant reversal of cirrhosis in patients with compensated cirrhosis (F4) following 96 weeks of treatment with EFX.
Reported topline week 96 data showing statistically significant histological improvements, demonstrating ≥1- and ≥2-stage fibrosis improvement without worsening of MASH at both 50mg and 28mg doses of EFX.
With gross proceeds of approximately $230M.
For the treatment of MASH.
Research article discussing the use of qFibrosis in early detection of fibrosis response in patients treated with EFX.
Study results showing the efficacy of EFX in improving fibrosis in cirrhotic patients.
Reported topline results demonstrating statistically significant reversal of cirrhosis in patients with compensated cirrhosis (F4) following 96 weeks of treatment with EFX.
Reported topline week 96 data showing statistically significant histological improvements, demonstrating ≥1- and ≥2-stage fibrosis improvement without worsening of MASH at both 50mg and 28mg doses of EFX.
With gross proceeds of approximately $230M.
For the treatment of MASH.
Research article discussing the use of qFibrosis in early detection of fibrosis response in patients treated with EFX.
Study results showing the efficacy of EFX in improving fibrosis in cirrhotic patients.